Fuso taps Otsuka as Japanese partner for cancer vaccine
This article was originally published in Scrip
Executive Summary
The Japanese firm Fuso Pharmaceutical Industries has sublicensed its pipeline cancer vaccine OTS102 to Otsuka Pharmaceutical for co-marketing in its home territory.